Pierantonio Menna

List of Publications by Year
in descending order

54	4,658	279778 23	149686 56
papers	citations	h-index	g-index

58	58	58	6984
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology. Advances in Pharmacology, 2022, , .	2.0	5
2	From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction. JACC: CardioOncology, 2022, 4, 139-140.	4.0	7
3	Cardiac Anthracycline Accumulation and B-Type Natriuretic Peptide to Define Risk and Predictors of Cancer Treatmentâ€“Related Early Diastolic Dysfunction. Journal of Pharmacology and Experimental Therapeutics, 2022, 381, 266-273.	2.5	1
4	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Leukemia, 2022, 36, 1215-1226.	7.2	19
5	High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rg BT /Overlock 10 Tf 5	3.5	6
6	The Reality of Pixantrone in Real Life. Acta Haematologica, 2021, 144, 244-245.	1.4	1
7	Safety and tolerability of a novel oral nutritional supplement in healthy volunteers. Clinical Nutrition, 2021, 40, 946-955.	5.0	4
8	Predictors of Early or Delayed Diastolic Dysfunction After Anthracycline-Based or Nonanthracycline Chemotherapy: A Pharmacological Appraisal. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 231-239.	2.5	5
9	Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life. Chemotherapy, 2021, 66, 47-52.	1.6	10
10	In Â®Entresto we trust. Cardio-Oncology, 2020, 6, 25.	1.7	3
11	Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Chemotherapy, 2020, 65, 35-41.	1.6	1
12	Efficacy and safety of low dose ponatinib in a case of Phâ€positive acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 187, e15-e17.	2.5	7
13	Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 197-205.	2.5	13
14	Cardiotoxicity of Targeted Cancer Drugs: Concerns, â€œThe Cart Before the Horse,â€•and Lessons from Trastuzumab. Current Cardiology Reports, 2019, 21, 33.	2.9	8
15	Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study. Chemotherapy, 2018, 63, 55-63.	1.6	23
16	Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy. Chemotherapy, 2018, 63, 35-38.	1.6	10
17	Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol Metabolites. Journal of Pharmacology and Experimental Therapeutics, 2018, 364, 323-331.	2.5	15
18	Isavuconazole: Case Report and Pharmacokinetic Considerations. Chemotherapy, 2018, 63, 253-256.	1.6	8

#	Article	IF	Citations
19	The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 518-527.	2.5	4
20	Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 158-168.	2.5	10
21	Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview. Chemotherapy, 2017, 62, 159-168.	1.6	59
22	Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose Doxorubicin. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 263-270.	2.5	15
23	Cancer drugs and QT prolongation: weighing risk against benefit. Expert Opinion on Drug Safety, 2017, 16, 1099-1102.	2.4	9
24	Do You Know Pixantrone?. Chemotherapy, 2017, 62, 192-193.	1.6	2
25	Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond Anthracyclines. Chemical Research in Toxicology, 2016, 29, 1270-1278.	3.3	20
26	The concomitant management of cancer therapy and cardiac therapy. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2727-2737.	2.6	43
27	Managing anthracycline-induced cardiotoxicity: beginning with the end in mind. Future Cardiology, 2015, 11, 363-366.	1.2	13
28	Low Level Tumor Necrosis Factor-Alpha Protects Cardiomyocytes Against High Level Tumor Necrosis Factor-Alpha: Brief Insight into a Beneficial Paradox. Cardiovascular Toxicology, 2014, 14, 387-392.	2.7	7
29	What is cardiotoxicity?. Progress in Pediatric Cardiology, 2014, 36, 3-6.	0.4	3
30	The Novel Anthracenedione, Pixantrone, Lacks Redox Activity and Inhibits Doxorubicinol Formation in Human Myocardium: Insight to Explain the Cardiac Safety of Pixantrone in Doxorubicin-Treated Patients. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 467-478.	2.5	50
31	Pharmacokinetic Characterization of Amrubicin Cardiac Safety in an Ex Vivo Human Myocardial Strip Model. II. Amrubicin Shows Metabolic Advantages over Doxorubicin and Epirubicin. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 474-483.	2.5	29
32	Pharmacokinetic Characterization of Amrubicin Cardiac Safety in an Ex Vivo Human Myocardial Strip Model. I. Amrubicin Accumulates to a Lower Level than Doxorubicin or Epirubicin. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 464-473.	2.5	11
33	Pharmacokinetics of Pegylated Liposomal Doxorubicin Administered by Intraoperative Hyperthermic Intraperitoneal Chemotherapy to Patients with Advanced Ovarian Cancer and Peritoneal Carcinomatosis. Drug Metabolism and Disposition, 2012, 40, 2365-2373.	3.3	18
34	Anthracycline cardiotoxicity. Expert Opinion on Drug Safety, 2012, 11, S21-S36.	2.4	161
35	Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. Autoimmunity Reviews, 2011, 10, 631-635.	5.8	50
36	Matters of the Heart: The Case of TNFÂ-Targeting Drugs. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2011, 11, 79-87.	3.4	3

#	Article	IF	Citations
37	Pharmacological Foundations of Cardio-Oncology. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 2-8.	2.5	81
38	Anthracycline Degradation in Cardiomyocytes: A Journey to Oxidative Survival. Chemical Research in Toxicology, 2010, 23, 6-10.	3.3	59
39	Doxorubicinolone Formation and Efflux: A Salvage Pathway against Epirubicin Accumulation in Human Heart. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 175-184.	2.5	21
40	4â€²-Epidoxorubicin To Re-explore Anthracycline Degradation in Cardiomyocytes. Chemical Research in Toxicology, 2009, 22, 978-983.	3.3	5
41	Cardiotoxicity of Antitumor Drugs. Chemical Research in Toxicology, 2008, 21, 978-989.	3.3	143
42	Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 790-800.	2.5	35
43	Doxorubicin Degradation in Cardiomyocytes. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 408-419.	2.5	38
44	Anthracycline Cardiotoxicity. Topics in Current Chemistry, 2007, 283, 21-44.	4.0	26
45	An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovascular Toxicology, 2007, 7, 80-85.	2.7	73
46	Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart. Journal of Biological Chemistry, 2006, 281, 10990-11001.	3.4	88
47	Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 424-433.	2.5	63
48	Oxidative Degradation of Cardiotoxic Anticancer Anthracyclines to Phthalic Acids. Journal of Biological Chemistry, 2004, 279, 5088-5099.	3.4	31
49	Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacological Reviews, 2004, 56, 185-229.	16.0	3,060
50	Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms. Methods in Enzymology, 2004, 378, 340-361.	1.0	101
51	Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity. British Journal of Pharmacology, 2003, 139, 641-651.	5.4	44
52	Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation:Â Implications for Cardiotoxicity of Anticancer Anthracyclines. Chemical Research in Toxicology, 2002, 15, 1179-1189.	3.3	32
53	Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue. British Journal of Pharmacology, 2001, 134, 1271-1278.	5.4	32
54	Anthracycline Metabolism and Toxicity in Human Myocardium: Comparisons between Doxorubicin, Epirubicin, and a Novel Disaccharide Analogue with a Reduced Level of Formation and [4Fe-4S] Reactivity of Its Secondary Alcohol Metabolite. Chemical Research in Toxicology, 2000, 13, 1336-1341.	3.3	68